Mosunetuzumab news

All news on Mosunetuzumab (also known as Lunsumio): plants, production capacities, investments and involved companies.

24 April 2026

Chugai Q1 FY2026 Results

Core rev ¥321.7B (+11.5%), core OP ¥163.3B (+17.1%), core net ¥118.6B (+19.6%). Launched Elevidys (DMD JP); Lunsumio+Polivy approved for LBCL. R&D: NXT007 switch, Enspryng (MOGAD), Foundayo US approval.
23 March 2026

Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma

Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
29 January 2026

Roche Reports 7% Sales Growth in 2025 Results

Pharmaceuticals and diagnostics drive profit and earnings growth. Key approvals and advancements in therapies. Dividend increase proposed. Board changes announced. Positive 2026 outlook.
22 December 2025

Roche's Lunsumio VELO Approved by FDA for Subcutaneous Use in Follicular Lymphoma

Lunsumio VELO cuts treatment time to one minute for relapsed follicular lymphoma, offering outpatient care with a manageable safety profile.
19 November 2025

Roche's Lunsumio SC Approved in EU for Relapsed Follicular Lymphoma

Lunsumio SC offers quick administration for relapsed follicular lymphoma, reducing treatment time to one minute with proven efficacy and safety.
19 September 2025

Roche's Lunsumio Subcutaneous Formulation Recommended for EU Approval

Lunsumio SC offers faster administration and high response rates for relapsed follicular lymphoma, with low cytokine release syndrome risk, pending EU approval.

Who will be producing Mosunetuzumab in the future?

Find out with chemXplore Alpha

Learn more